Making medicines safer--the need for an independent drug safety board.
Making medicines safer--the need for an independent drug safety board.
复制标题
让药品更安全——需要独立的药品安全委员会。
DOI：
10.1056/nejm199812173392512
复制
发表时间：
1998
期刊：
影响因子：
--
通讯作者：
Woosley,R
中科院分区：
文献类型：
--
作者：
Wood,AJ;Stein,CM;Woosley,R
1997年，由于人们猜测，使用右芬氟拉明（Redux）的数百万人可能会受到伤害，因此右芬氟拉明（Redux）于1997年撤出美国市场。1 - 3最近，米贝拉地尔（Posicor）被撤出，因为有人认为它可能与其他药物发生严重的相互作用。最近估计，每年约有10万美国人死于此类不良反应，5使其成为最常见的死亡原因之一。独立的机构存在，调查航空事故，铁路事故，辐射泄漏，并提出建议。
Dexfenfluramine (Redux) was withdrawn from the market in the United States in 1997 amid speculation that millions who used it could have been harmed.1–3More recently, mibefradil (Posicor) was withdrawn because of suggestions that it may have serious interactions with other drugs.4Adverse reactions to drugs are an important cause of morbidity and mortality; it has been estimated recently that approximately 100,000 Americans die every year as a result of such adverse reactions,5making them one of the most common causes of death. Independent agencies exist to investigate airline accidents, railroad mishaps, and radiation spills and to make recommendations . . .